<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041249</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-62011</org_study_id>
    <secondary_id>EORTC-62011</secondary_id>
    <nct_id>NCT00041249</nct_id>
  </id_info>
  <brief_title>Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma</brief_title>
  <official_title>Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who
      have locally advanced or metastatic soft tissue sarcoma that has not responded to one
      previous chemotherapy regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the antitumor activity of brostallicin, in terms of objective response, in
           patients with locally advanced or metastatic soft tissue sarcoma who have failed one
           prior chemotherapy treatment.

        -  Determine the time to progression and duration of response in patients treated with this
           drug.

        -  Determine the safety and toxic effects of this drug in these patients.

        -  Correlate clinical outcome with whole blood glutathione level in patients treated with
           this drug.

      OUTLINE: This is a multicenter study. Patients are stratified according to tumor (tumors
      other than gastrointestinal stromal tumor (GIST) vs GIST).

      Patients receive brostallicin IV over 10 minutes on day 1. Treatment repeats every 21 days
      for at least 4 courses in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 2 months for 1 year and then every 4 months for 1 year.

      PROJECTED ACCRUAL: A total of 58-72 patients (40 for stratum I and 18-32 for stratum II) will
      be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">64</enrollment>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brostallicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed soft tissue sarcoma that is not amenable to surgery,
             radiotherapy, or combined modality therapy with curative intent

          -  Stratum I

               -  Malignant fibrous histiocytoma

               -  Liposarcoma

               -  Rhabdomyosarcoma

               -  Synovial sarcoma

               -  Malignant paraganglioma

               -  Fibrosarcoma

               -  Leiomyosarcoma

               -  Angiosarcoma including hemangiopericytoma

               -  Malignant peripheral nerve sheath tumor

               -  Unclassified sarcoma

               -  Miscellaneous sarcoma

          -  Stratum II

               -  Gastrointestinal stromal tumor

               -  Previously treated with imatinib mesylate for locally advanced or metastatic
                  disease and demonstrated disease progression

          -  The following sarcoma types are excluded:

               -  Mixed mesodermal tumors of the uterus (and carcinosarcoma)

               -  Chondrosarcoma

               -  Malignant mesothelioma

               -  Neuroblastoma

               -  Osteosarcoma

               -  Ewing's sarcoma

               -  Embryonal rhabdomyosarcoma

          -  At least one measurable lesion

          -  Progressive disease after 1 prior anthracycline- and/or alkylating-containing
             chemotherapy regimen for locally advanced or metastatic disease

          -  Clinical evidence of progression within 6 weeks prior to study treatment

          -  No known or symptomatic CNS metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 15

        Performance status:

          -  WHO 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 4,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)

          -  SGPT and SGOT no greater than 3 times ULN

          -  Alkaline phosphatase no greater than 2.5 times ULN

        Renal:

          -  Creatinine no greater than 1.4 mg/dL OR

          -  Creatinine clearance greater than 65 mL/min

        Cardiovascular:

          -  No prior severe cardiovascular disease

        Other:

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for up to 6 months after
             study

          -  No other prior or concurrent malignancy except adequately treated basal cell skin
             cancer or carcinoma in situ of the cervix

          -  No other severe medical illness

          -  No psychosis

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent biologic response modifiers or immunotherapy

          -  No concurrent prophylactic hematopoietic growth factors (e.g., filgrastim (G- CSF) or
             sargramostim (GM-CSF)

        Chemotherapy:

          -  See Disease Characteristics

          -  More than 4 weeks since prior chemotherapy and recovered

          -  Prior adjuvant chemotherapy as first-line treatment allowed provided disease
             progressed within 6 months after the completion of chemotherapy

          -  No prior ecteinascidin 743 (stratum I)

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  No concurrent hormonal therapy

        Radiotherapy:

          -  See Disease Characteristics

          -  Recovered from prior radiotherapy

          -  No prior radiotherapy to sole measurable lesion

          -  Concurrent palliative radiotherapy to nontarget lesions allowed at investigator's
             discretion

        Surgery:

          -  See Disease Characteristics

          -  Recovered from prior surgery

        Other:

          -  No other concurrent anticancer therapy (approved or investigational)

          -  No concurrent participation in any other clinical treatment study

          -  No other concurrent investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Leahy, MBChB, FRACP, FRCP, FRC Path</last_name>
    <role>Study Chair</role>
    <affiliation>Fremantle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Roessle Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>D-13122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Krankenhaus Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern der Ludwig-Maximilians Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Treatment at Newcastle General Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Leahy M, Ray-Coquard I, Verweij J, Le Cesne A, Duffaud F, Hogendoorn PC, Fowst C, de Balincourt C, di Paola ED, van Glabbeke M, Judson I, Blay JY; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2007 Jan;43(2):308-15. Epub 2006 Nov 13.</citation>
    <PMID>17095209</PMID>
  </results_reference>
  <results_reference>
    <citation>Leahy MG, Blay JY, Verweij J, et al.: EORTC 62011: phase II trial of brostallicin for soft tissue sarcoma. [Abstract] Eur J Cancer Suppl 1 (5): S209, A-694, 2003.</citation>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult angiosarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult liposarcoma</keyword>
  <keyword>adult neurofibrosarcoma</keyword>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <keyword>adult malignant hemangiopericytoma</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

